Statement of Commissioner Rebecca Kelly Slaughter Regarding 6(b) Study of Pharmacy Benefit Managers
Date
By
Rebecca Kelly Slaughter, Commissioner
Matter Number
P221200
Displaying 101 - 120 of 1466
FTC Sues to Block Merger Between Utah Healthcare Rivals HCA Healthcare and Steward Health Care System
Date
The Federal Trade Commission has authorized an administrative complaint and a lawsuit in federal court to block the proposed merger between Utah healthcare competitors HCA Healthcare and Steward...
FTC Sues to Block Merger Between New Jersey Healthcare Rivals RWJBarnabas Health and Saint Peter’s Healthcare System
Date
The Federal Trade Commission authorized an administrative complaint and a suit in federal court to block the acquisition of Saint Peter’s Healthcare System by RWJBarnabas Health, or RWJ, which is one...
FTC and Justice Department to Hold Two-Day Virtual Public Workshop Examining Antitrust Enforcement in the Pharmaceutical Industry
Date
The Federal Trade Commission and the U.S. Department of Justice (DOJ) will host a two-day workshop to explore new approaches to enforcing the antitrust laws in the pharmaceutical industry. The...
Federal Register Notice
Medtronic/Intersect ENT; Analysis of Agreement Containing Consent Orders To Aid Public Comment
Date
FTC Acts to Protect Patients Who Rely on Medical Instruments Used in Sinus Procedures
Date
The Federal Trade Commission took action today to protect patients who rely on medical instruments used in sinus procedures. The FTC’s order requires Medtronic, Inc. to divest a subsidiary of...
Federal Register Notice
Hikma Pharmaceuticals PLC/Custopharm, Inc.; Analysis of Agreement Containing Consent Orders To Aid Public Comment
Date
Federal Trade Commission Preserves Competition for Development and Marketing of Steroid Injectable Drug
Date
The Federal Trade Commission today required – as a condition of Hikma Pharmaceuticals PLC’s $375 million acquisition of Custopharm, Inc. – that Custopharm’s parent company retain and transfer...
Statement of Federal Trade Commission Bureau of Competition Deputy Director John M. Newman on Federal Appeals Court Ruling Affirming Preliminary Injunction to Halt Merger of New Jersey Hospital Networks
Date
Federal Trade Commission Bureau of Competition Deputy Director John M. Newman issued this statement regarding the U.S. Court of Appeals for the Third Circuit decision affirming the district court’s...
Statement Regarding Termination of Attempted Merger of Rhode Island’s Two Largest Healthcare Providers
Date
In response to the announcement that Lifespan Corp. (“Lifespan”) and Care New England Health System (“Care New England”) have terminated their proposed merger, FTC Bureau of Competition Director Holly...
Lifespan/CNE, In the Matter of
The Federal Trade Commission authorized an administrative complaint, and a suit in federal court blocking the proposed merger of Rhode Island’s two largest healthcare providers. The agency alleged the deal would lead to higher prices and lower quality care. The FTC, jointly with the Rhode Island Office of the Attorney General, filed a complaint in federal district court seeking a temporary restraining order and preliminary injunction to stop the deal and to maintain the status quo pending an administrative trial on the merits of the case. On March 2, 2022, the Commission issued a statement regarding the parties’ decision to abandon the transaction.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
211 0031
Docket Number
9406
Case Status
Pending
FTC Approves Modifications to Boston Scientific Corp. Divestiture Agreement
Date
The Federal Trade Commission has approved certain modifications to medical device company Boston Scientific Corp.’s Divestiture Agreements. The FTC approved these agreements and incorporated them into...
Boston Scientific and BTG, In the Matter of
Medical device company Boston Scientific Corp. agreed to divest certain assets to Varian Medical Systems to settle Federal Trade Commission charges that Boston Scientific’s proposed $4.2 billion acquisition of medical equipment and pharmaceutical supplier BTG plc would violate federal antitrust law. According to the complaint, Boston Scientific’s acquisition of BTG would harm consumers in the U.S. market for drug eluting beads, or DEBs, which are microscopic beads used to treat certain liver cancers. Interventional radiologists use DEBs, combined with chemotherapy drugs, in a procedure called transarterial chemoembolization. Under the proposed settlement agreement, Boston Scientific was required to divest to Varian its DEB business, as well as its bland bead product line. Bland beads are used in another type of procedure to block the flow of blood to a liver tumor. On Feb. 18, 2022, the Commission announced modifications to the divestiture agreement with Boston Scientific Corp.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
191 0039
Docket Number
C-4684
Case Status
Pending
Concurring Statement of Commissioner Slaughter and Chair Khan regarding FTC and State of Rhode Island v. Lifespan Corporation and Care New England Health System
Date
By
Lina M. Khan, Chair;
Rebecca Kelly Slaughter, Commissioner
Matter Number
2110031
File
Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding Lifespan Corporation and Care New England Health System
Date
By
Christine S. Wilson, Former Commissioner;
Noah Joshua Phillips, Former Commissioner
Matter Number
211 0031
Docket Number
9406
File
Text of the Statement
(161.54 KB)
FTC and Rhode Island Attorney General Step in to Block Merger of Rhode Island’s Two Largest Healthcare Providers
Date
The Federal Trade Commission has authorized an administrative complaint , and authorized a suit in federal court, to block the proposed merger of Rhode Island’s two largest healthcare providers...
Stopping COVID-19 Fraud and Price Gouging
Date
By
Samuel Levine, Director, Bureau of Consumer Protection
Matter Number
P210100
File
Text of the Commission Testimony
(299.73 KB)
FTC Comment to Food and Drug Administration Supports Agency’s Proposed Rule on Establishing Over-the-Counter Hearing Aids
Date
The Federal Trade Commission staff has submitted a comment to the Food and Drug Administration (FDA) in response to FDA’s request for comment on its proposed rule on establishing over-the-counter...
Vision Path, Inc., Online Seller of Hubble Lenses, Settles Charges it Violated the Contact Lens Rule and FTC Act to Boost Sales
Date
New York City-based Vision Path, Inc., the online seller of direct-to-consumer Hubble lenses, will pay penalties and redress totaling $3.5 million to settle Federal Trade Commission charges that it...
Plain Language Guidance
Soliciting and Paying for Online Reviews: A Guide for Marketers
Date
Businesses and consumers both rely on online reviews. Companies may need good ones to attract customers, while consumers often use them to decide what to buy or who to hire. People should be able to...
File
Displaying 101 - 120 of 1466